I Rhythm Technologies, Inc. IRTC
We take great care to ensure that the data presented and summarized in this overview for iRhythm Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRTC
View all-
Sands Capital Management, LLC Arlington, VA3.18MShares$321 Million0.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.14MShares$317 Million0.01% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.76MShares$279 Million0.4% of portfolio
-
Black Rock Inc. New York, NY2.5MShares$253 Million0.01% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.64MShares$165 Million0.03% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A61.38MShares$140 Million0.18% of portfolio
-
State Street Corp Boston, MA949KShares$95.8 Million0.0% of portfolio
-
Bnp Paribas Asset Management Holding S.A.900KShares$90.9 Million0.2% of portfolio
-
Westfield Capital Management CO LP Boston, MA765KShares$77.3 Million0.32% of portfolio
-
Eventide Asset Management, LLC Boston, MA739KShares$74.7 Million1.28% of portfolio
Latest Institutional Activity in IRTC
Top Purchases
Top Sells
About IRTC
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Transactions at IRTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 03
2025
|
Mervin Smith EVP Strategic Business Ops |
SELL
Open market or private sale
|
Direct |
638
-3.73%
|
$68,904
$108.77 P/Share
|
|
Mar 03
2025
|
Marc W. Rosenbaum Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
314
-2.66%
|
$33,912
$108.77 P/Share
|
|
Mar 03
2025
|
Quentin S. Blackford President and CEO |
SELL
Open market or private sale
|
Direct |
8,145
-3.76%
|
$879,660
$108.77 P/Share
|
|
Mar 03
2025
|
Daniel G. Wilson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,341
-4.91%
|
$252,828
$108.77 P/Share
|
|
Mar 03
2025
|
Minang Turakhia EVP, CMO & CSO |
SELL
Open market or private sale
|
Direct |
2,467
-5.49%
|
$266,436
$108.77 P/Share
|
|
Mar 03
2025
|
Sumi Shrishrimal EVP, Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
1,726
-4.56%
|
$186,408
$108.77 P/Share
|
|
Mar 03
2025
|
Chad Patterson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,756
-4.5%
|
$297,648
$108.77 P/Share
|
|
Mar 03
2025
|
Patrick Michael Murphy CBO and CLO |
SELL
Open market or private sale
|
Direct |
3,075
-5.23%
|
$332,100
$108.77 P/Share
|
|
Feb 26
2025
|
Minang Turakhia EVP, CMO & CSO |
SELL
Open market or private sale
|
Direct |
7,014
-13.49%
|
$785,568
$112.13 P/Share
|
|
Feb 26
2025
|
Minang Turakhia EVP, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
11,220
+17.75%
|
-
|
|
Feb 26
2025
|
Sumi Shrishrimal EVP, Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
7,942
-17.35%
|
$889,504
$112.13 P/Share
|
|
Feb 26
2025
|
Sumi Shrishrimal EVP, Chief Risk Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,732
+12.82%
|
-
|
|
Feb 26
2025
|
Marc W. Rosenbaum Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,141
+20.99%
|
-
|
|
Feb 26
2025
|
Chad Patterson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,229
-17.77%
|
$1,481,648
$112.13 P/Share
|
|
Feb 26
2025
|
Chad Patterson Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,118
+14.0%
|
-
|
|
Feb 26
2025
|
Mervin Smith EVP Strategic Business Ops |
BUY
Grant, award, or other acquisition
|
Direct |
6,732
+28.26%
|
-
|
|
Feb 26
2025
|
Daniel G. Wilson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,512
-5.01%
|
$281,344
$112.13 P/Share
|
|
Feb 26
2025
|
Daniel G. Wilson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,976
+15.18%
|
-
|
|
Feb 26
2025
|
Quentin S. Blackford President and CEO |
SELL
Open market or private sale
|
Direct |
22,252
-9.31%
|
$2,492,224
$112.13 P/Share
|
|
Feb 26
2025
|
Quentin S. Blackford President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
38,599
+13.9%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 248K shares |
|---|---|
| Open market or private purchase | 6.94K shares |
| Other acquisition or disposition | 576 shares |
| Open market or private sale | 118K shares |
|---|